{"id":154216,"date":"2025-06-03T07:25:13","date_gmt":"2025-06-03T07:25:13","guid":{"rendered":"https:\/\/www.europesays.com\/uk\/154216\/"},"modified":"2025-06-03T07:25:13","modified_gmt":"2025-06-03T07:25:13","slug":"uk-pharmacies-struggle-with-severe-creon-shortage","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/uk\/154216\/","title":{"rendered":"UK Pharmacies Struggle with Severe Creon Shortage"},"content":{"rendered":"<p>Nearly all UK pharmacies are experiencing severe \u201cchallenges\u201d supplying pancreatic enzyme replacement therapy (PERT), the National Pharmacy Association (NPA) warned.\u00a0<\/p>\n<p>A sample survey by the association found that 96% of pharmacies were struggling to obtain Creon (<a href=\"https:\/\/reference.medscape.com\/drug\/creon-pancreaze-pancrelipase-342069\" class=\"cl_ref_drugs\" target=\"_blank\" rel=\"noopener\">pancrelipase<\/a>, Viatris). A further 89% reported difficulties supplying PERT alternatives.<\/p>\n<p>Patients Resorting to Extreme Measures<\/p>\n<p>The ongoing shortage has forced patients to take desperate action, according to the NPA, which said some are rationing existing medication supplies or skipping meals entirely.<\/p>\n<p>One pharmacist described it as the \u201cworst stock shortage\u201d they had ever encountered. Patients report eating only one meal daily, contacting multiple pharmacies for supplies, or travelling more than 30 miles to obtain the medication.<\/p>\n<p>Critical Medication for Serious Conditions<\/p>\n<p>Creon is used to treat pancreatic exocrine insufficiency from a variety of causes, including <a href=\"https:\/\/emedicine.medscape.com\/article\/280605-overview\" class=\"cl_ref_article\" target=\"_blank\" rel=\"noopener\">pancreatic cancer<\/a>, <a href=\"https:\/\/emedicine.medscape.com\/article\/1001602-overview\" class=\"cl_ref_article\" target=\"_blank\" rel=\"noopener\">cystic fibrosis<\/a>, and pancreatitis.\u00a0<\/p>\n<p>The medication, derived from porcine pancreatin, contains <a href=\"https:\/\/emedicine.medscape.com\/article\/2088094-overview\" class=\"cl_ref_article\" target=\"_blank\" rel=\"noopener\">lipase<\/a>, protease, and <a href=\"https:\/\/emedicine.medscape.com\/article\/2054386-overview\" class=\"cl_ref_article\" target=\"_blank\" rel=\"noopener\">amylase<\/a>. It dissolves rapidly in the stomach to release its enzyme load in the small intestine, where its lipolytic, amylolytic, and proteolytic activity enable absorption of the products of pancreatic digestion.<\/p>\n<p>PERT medications need to be taken to facilitate digestion every time a patient eats. In clinical trials, treatment with Creon markedly improved stool consistency, abdominal pain, and stool frequency, independent of the underlying disease.<\/p>\n<p>The consequences of inadequate dosing can be severe. Patients may become too unwell for surgery, struggle with chemotherapy tolerance, or experience debilitating symptoms that diminish quality of life. Symptoms may include diarrhoea, flatulence, bloating, abdominal pain, unexplained weight loss, and oily, foul-smelling stools (steatorrhoea).\u00a0<\/p>\n<p>Safety Concerns<\/p>\n<p>Olivier Picard, NPA chair, warned the shortage has \u201cprofound effects\u201d on patients who depend on the medication to survive and lead normal lives. \u201cIt simply cannot be right that in the 21st century patients are skipping meals in order to ration their medication,\u201d he said.<\/p>\n<p>Last week, the government extended the current <a href=\"https:\/\/www.nhsbsa.nhs.uk\/pharmacies-gp-practices-and-appliance-contractors\/serious-shortage-protocols-ssps\" target=\"_blank\" rel=\"noopener\">Serious Shortage Protocol<\/a> (SSP) for Creon until November 21, 2025. The protocol allows pharmacists to use professional judgement to decide whether it&#8217;s \u201creasonable and appropriate\u201d to substitute a patient&#8217;s prescription for an alternative agent for one dispensing month. It allows pharmacies to supply a reduced quantity of Creon capsules that might be in stock without having to send a patient back to their GP to get a new prescription.\u00a0<\/p>\n<p>Two SSPs for Creon 10,000 and 25,000 capsules have been in place since May 2024. However, the survey found that 81% of pharmacies felt the current arrangements for managing the shortage were inadequate. Pharmacists were still obliged to refer patients back to prescribers when seeking PERT alternatives.\u00a0<\/p>\n<p>Alternative PERT formulations, Nutrizym and Pancrex, are also now in short supply as manufacturers struggle to meet demand.\u00a0<\/p>\n<p>GPs and pharmacies can order unlicensed Creon or other PERT products from overseas, but other countries have experienced similar shortages.<\/p>\n<p>Calls for Regulatory Change<\/p>\n<p>The NPA and <a href=\"https:\/\/emedicine.medscape.com\/article\/280605-overview\" class=\"cl_ref_article\" target=\"_blank\" rel=\"noopener\">Pancreatic Cancer<\/a> UK issued a joint statement urging government action. They called for a national plan to address shortages and support patients with alternative care.<\/p>\n<p>Picard said that, although the situation was complex and not the fault of the government, medicine shortages were all too common. \u201cHighly trained pharmacists should also be permitted to use their professional judgment to supply alternative medicines \u2014 where it is safe and appropriate \u2014 in the event of the prescribed version being unavailable.\u201d<\/p>\n<p>Alfie Bailey-Bearfield, head of influencing and health improvement at Pancreatic Cancer UK, said that the findings were \u201cdeeply worrying.\u201d\u00a0<\/p>\n<p>It was \u201ctotally unacceptable\u201d that cancer patients were still taking desperate measures that put their health, wellbeing, and eligibility for treatment at risk, when the charity had been raising concerns with Department of Health and Social Care (DHSC) officials and PERT suppliers for more than a year. \u201cThis crisis continues to put people&#8217;s health on the line, and they cannot afford to wait any longer,\u201d he said.<\/p>\n<p>A DHSC spokesperson said that the supply issues with Creon were European-wide and caused by limited availability of raw ingredients along with manufacturing capacity constraints. \u201cWe are working closely with the industry and the NHS to mitigate the impact on patients and resolve the issues as quickly as possible,\u201d the spokesperson said.<\/p>\n<p>Dr Sheena Meredith is an established medical writer, editor, and consultant in healthcare communications, with extensive experience writing for medical professionals and the general public. She is qualified in medicine and in law and medical ethics.\u00a0<\/p>\n","protected":false},"excerpt":{"rendered":"Nearly all UK pharmacies are experiencing severe \u201cchallenges\u201d supplying pancreatic enzyme replacement therapy (PERT), the National Pharmacy Association&hellip;\n","protected":false},"author":2,"featured_media":154217,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4315],"tags":[1204,65632,27471,65633,105,27470,27472,65631,4326,65634,35587,211,26425,65630,16,35584,35586,20530,15,35585],"class_list":{"0":"post-154216","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-medication","8":"tag-cancer","9":"tag-cancer-of-the-pancreas","10":"tag-carcinoma","11":"tag-drug-shortages","12":"tag-health","13":"tag-malignant-neoplasia","14":"tag-malignant-neoplasm","15":"tag-malignant-pancreatic-neoplasm","16":"tag-medication","17":"tag-medication-shortages","18":"tag-national-health-service","19":"tag-nhs","20":"tag-pancreatic-cancer","21":"tag-pancreatitis","22":"tag-uk","23":"tag-uk-national-health-service","24":"tag-uk-nhs","25":"tag-uk-site-content-united-kingdom-site-content","26":"tag-united-kingdom","27":"tag-united-kingdom-national-health-service"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@uk\/114618245037121731","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/154216","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/comments?post=154216"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/154216\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media\/154217"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media?parent=154216"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/categories?post=154216"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/tags?post=154216"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}